Arrowhead Pharmaceuticals, Inc. annual operating income for fiscal 2025 was $98 million, compared with -$601 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Operating Income (EBIT) | $98M | ($601M) | ($205M) | ($178M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($141M) | $41M | $44M | ($166M) | $381M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More ARWR metrics: Revenue · Net Income · EPS · Free Cash Flow
All ARWR financial statements → Interactive ARWR charts →
About TickerBase · Data methodology & sources